Unprecedented partnership to raise awareness of women’s brain health challenges and significantly expand funding for sex-based brain health research 

Media Advisory

International Leaders Gather at WomenAgainstAlzheimer’s Summit to Push for an Alzheimer’s Cure by 2020

New data to be released about the disproportionate burden on families in providing Alzheimer’s care

Senator Barbara Mikulski, Senator Elizabeth Warren, and lifestyle expert, TV personality, and Alzheimer’s victim B. Smith among women to be honored at “Out of the Shadows” Dinner

Save the Date

WomenAgainstAlzheimer's is part of the UsAgainstAlzheimer's Network and harnesses the powerful and creative voice of women across the country and abroad to find a cure for Alzheimer's by 2025. We believe that it is time to bring Alzheimer's Out of the Shadows and into our conversations with policymakers, researchers, colleagues, and community leaders.

Anna Palmer

January 16, 2015 -- usalzheimeradmin

Anna Palmer is a senior Washington correspondent for POLITICO, where she covers the nexus of politics, money and corporate interests. POLITICO is a nonpartisan, Washington-based political journalism organization, a one-stop shop for fast, in-depth coverage of the White House, Congress, politics and policy. Anna previously served as co-author of the daily newsletter, POLITICO Influence, considered a must-read on K Street.

Berna Huebner

January 16, 2015 -- usalzheimeradmin

Berna Huebner is the founder of the Hilgos Foundation, which supports and encourages the ongoing process of artistic creation in people with dementia, including Alzheimer’s. She co-directed the film and edited the book I Remember Better When I Paint, which examines the positive impact of art on people with Alzheimer’s and shows how the creative arts can help Alzheimer’s patients re-engage in life. Berna is director of the Center for the Study of International Communications in Paris, France.

Olivia Mastry, JD, MPH

January 16, 2015 -- usalzheimeradmin

Olivia Mastry is currently serving as Executive Lead for ACT on Alzheimer’s, a Minnesota statewide collaboration involving more than 60 organizations and 500 individuals seeking to transform Minnesota’s medical and long-term care systems and communities to support individuals with Alzheimer’s disease and their families.  Olivia combines her training and experience in law, health administration, public health and conflict resolution to facilitate multi-stakeholder collaborations and focuses her work on achieving large-scale systems change through a unique collaborative

Abby Cox

January 16, 2015 -- usalzheimeradmin

Abigail Cox is director of the Georgia Gerontology Society (GGS), the largest state organization of multidisciplinary professionals in the field of aging. At GGS, she has prioritized advocacy and education about mental health, aging and Alzheimer’s/dementia. Her career includes roles at the Georgia Division of Aging Services, Care Improvement Plus, and the Georgia Council on Aging.

Maike Stenull

January 16, 2015 -- usalzheimeradmin

Maike Stenull is the Senior Director, Strategic Projects and Transformational Leadership at the Office of the Chief Medical Officer at Johnson & Johnson. She leads and manages cross-sector, cross-functional initiatives and drives process, content and business impact for large, transformational projects. She is the Decision Support Lead for J&J’s R&D Management Committee and the co-lead on the Global Alzheimer’s Platform work stream focused on alternative finance options. Previously, she was Finance Controller for Neuroscience Therapeutics for Janssen R&D.

Diana Shineman, PhD

January 16, 2015 -- usalzheimeradmin

Dr. Shineman is director for scientific affairs at the Alzheimer’s Drug Discovery Foundation, where she develops and manages the Foundation’s drug discovery and development grant programs and strategic initiatives. The ADDF works strategically with foundations, government and industry partners to tackle unmet needs. Projects funded by the ADDF have garnered nearly $2 billion in follow-on funding. Diana joined the ADDF in 2008. She has authored numerous articles and peer-reviewed publications and maintains various professional memberships. She earned a Ph.D.

Anna Shadman

January 16, 2015 -- usalzheimeradmin

Anna Shadman is the compound development team leader for Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI), leading the development strategy and execution of the Alzheimer’s Immunotherapy Program portfolio of compounds within an alliance. She is also the site head for San Francisco and a member of the Janssen AI board of directors. She joined Johnson & Johnson in 2005, holding leadership positions in Janssen Global Clinical Operations and Janssen AI, overseeing operational activities for complex Alzheimer’s clinical trials.


^ Back to Top